Takeda Pharmaceutical (4502) financial statements

+149.3%since 2016
FY2026 revenue
¥4.5T▼ −1.7%
FY2026 net income
−¥152.4B▼ −241.2%
FY2026 diluted EPS
−¥96.75▼ −243.9%
FY2026 free cash flow
¥865.4B▲ +1.1%

Takeda Pharmaceutical income statement

Takeda Pharmaceutical income statement
JPY millionsFY2026FY2025FY2024
Period ended31 Mar 202631 Mar 202531 Mar 2024
Revenue4,505,7204,581,5514,263,762
Gross profit (derived)2,934,1323,001,3342,837,084
Operating income6,217342,586214,075
Pretax income-142,355175,08452,791
Net income-152,390107,928144,067
Diluted earnings per share-96.7567.2391.16

Takeda Pharmaceutical balance sheet

Takeda Pharmaceutical balance sheet
JPY millionsFY2026FY2025FY2024
Period ended31 Mar 202631 Mar 202531 Mar 2024
Cash and cash equivalents595,054385,113457,800
Total assets15,511,50614,248,34415,108,792
Total liabilities8,080,8587,312,3657,834,788
Total equity7,430,6496,935,9797,274,005
Long-term debt4,369,6813,966,3264,476,501

Takeda Pharmaceutical cash flow statement

Takeda Pharmaceutical cash flow statement
JPY millionsFY2026FY2025FY2024
Period ended31 Mar 202631 Mar 202531 Mar 2024
Operating cash flow1,041,4311,057,182716,344
Capital expenditure-176,003-200,795-175,420
Free cash flow (derived)865,428856,387540,924
Dividends paid-311,901-302,498-287,188
Share repurchases-51,603-51,860-2,326

Half-year highlights

Half-year highlights
JPY millionsH1 FY2027H1 FY2026H1 FY2025H1 FY2024
Period ended30 Sep 202630 Sep 202530 Sep 202430 Sep 2023
Revenue2,406,9972,219,4812,384,0282,101,707
Operating income406,739253,561350,576119,230
Net income305,626112,441187,29441,365
Diluted earnings per share189.5270.45117.1126.29
Operating cash flow431,890593,651451,267291,305
Total assets15,271,49814,470,30014,573,00014,871,889

Takeda Pharmaceutical major shareholders

Takeda Pharmaceutical major shareholders
HolderShare of classSharesFiled
ブラックロック・ジャパン株式会社9.2%147,133,95721 October 2026
三井住友トラスト・アセットマネジメント株式会社5.3%83,841,06319 September 2025

Takeda Pharmaceutical EDINET filings

Takeda Pharmaceutical EDINET filings
FiledFormType
29 October 2026Semiannual Securities ReportHalf-year report
26 June 2026Extraordinary ReportCurrent report
17 June 2026Annual Securities ReportAnnual report
19 May 2026Extraordinary ReportCurrent report
30 October 2025Semiannual Securities ReportHalf-year report
1 July 2025Extraordinary ReportCurrent report
25 June 2025Annual Securities ReportAnnual report
30 January 2025Extraordinary ReportCurrent report

Common questions

What was Takeda Pharmaceutical's revenue in fiscal 2026?

Takeda Pharmaceutical reported ¥4.5 trillion in revenue for fiscal 2026, the year ended 31 March 2026, down 1.7% from fiscal 2025.

What was Takeda Pharmaceutical's net income in fiscal 2026?

Takeda Pharmaceutical reported a net loss of ¥152.4 billion for fiscal 2026, the year ended 31 March 2026. Diluted earnings per share were −¥96.75.

What was Takeda Pharmaceutical's free cash flow in fiscal 2026?

Takeda Pharmaceutical had ¥865.4 billion in free cash flow in fiscal 2026. Operating cash flow was ¥1.0 trillion and capital expenditure was ¥176.0 billion.

What were Takeda Pharmaceutical's total assets at the end of fiscal 2026?

Takeda Pharmaceutical reported total assets of ¥15.5 trillion at the end of fiscal 2026, the year ended 31 March 2026.

How much Takeda Pharmaceutical history do I get?

Every account gets the full history, annual and semiannual, with first reported values and as of dates.